Ignite Creation Date:
2025-12-24 @ 3:32 PM
Ignite Modification Date:
2026-02-22 @ 4:53 PM
Study NCT ID:
NCT05999292
Status:
TERMINATED
Last Update Posted:
2024-12-09
First Post:
2023-07-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Study of 68Ga-R8760
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D018268', 'term': 'Adrenocortical Carcinoma'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D000306', 'term': 'Adrenal Cortex Neoplasms'}, {'id': 'D000310', 'term': 'Adrenal Gland Neoplasms'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D000303', 'term': 'Adrenal Cortex Diseases'}, {'id': 'D000307', 'term': 'Adrenal Gland Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 11}}, 'statusModule': {'whyStopped': 'Sponsor decision', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2023-09-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-12', 'completionDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-12-04', 'studyFirstSubmitDate': '2023-07-27', 'studyFirstSubmitQcDate': '2023-08-11', 'lastUpdatePostDateStruct': {'date': '2024-12-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-08-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of adverse events characterized overall and by type, frequency, seriousness, relationship to study drug, timing and severity graded according to the NCI-CTCAE v5.0; absolute values and changes in clinical laboratory parameters', 'timeFrame': '7 days'}, {'measure': 'Absorbed dose coefficients (milliGray [mGy]/megabecquerel [MBq]) in organs', 'timeFrame': '1 day'}, {'measure': 'The effective dose (milliSievert [mSv]/MBq)', 'timeFrame': '1 day'}], 'secondaryOutcomes': [{'measure': 'Number and location of tumors identified by 68Ga-R8760 PET/CT and by anatomic images', 'timeFrame': '1 day'}, {'measure': 'Maximum standard uptake value (SUVmax) of each tumor and of source organ', 'timeFrame': '1 day'}, {'measure': 'Ratio of the tumor SUV over reference region SUV', 'timeFrame': '1 day'}, {'measure': 'Area under the plasma concentration versus time curse (AUC)', 'timeFrame': '1 day'}, {'measure': 'Maximum plasma concentration (Cmax)', 'timeFrame': '1 day'}, {'measure': 'Half-life (T1/2) of 68Ga-R8760', 'timeFrame': '1 day'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Adrenocortical Carcinoma'], 'conditions': ['Adrenocortical Carcinoma']}, 'descriptionModule': {'briefSummary': 'A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Adrenocortical Carcinoma Subjects\n\nInclusion Criteria:\n\n1. Pathologically or clinically confirmed ACC.\n2. Newly diagnosed or recurrent/relapsed ACC with at least 1 measurable target lesion per RECIST v1.1 criteria.\n3. Male or non-pregnant, non-lactating female subjects age ≥18 years.\n4. Female subjects of childbearing potential and male subjects (if sexually active) must agree to use adequate method(s) of effective contraception during their participation in the study.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.\n6. Adequate hepatic function as defined below:\n\n 1. Serum alanine aminotransaminase (ALT)/ aspartate aminotransaminase (AST) ≤3 × upper limit of normal (ULN) or ≤5 × ULN if liver metastases are present or received prior mitotane therapy, and\n 2. Serum bilirubin - total ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis in which case total ≤3.0 × ULN).\n7. Adequate renal function as measured by creatinine clearance calculated by the Cockcroft-Gault formula (≥60 mL/minute).\n8. Able to understand and willing to sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Administered a radionuclide within a period of time corresponding to less than 10 physical half-lives of the radionuclide prior to study Day 1.\n2. Radiotherapy ≤14 days prior to study Day 1.\n3. Major surgery ≤21 days prior to study Day 1 or has not recovered from adverse effects of such procedure.\n4. Severe or unstable medical condition, such as congestive heart failure (New York Heart Association \\[NYHA\\] Class III or IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, as well as an uncontrolled cardiac arrhythmia requiring medication (≥Grade 2, according to NCI-CTCAE Version 5.0), myocardial infarction within 6 months prior to starting study drug, or any other significant or unstable concurrent cardiac illness. Note: Stable chronic atrial fibrillation is allowed.\n5. Congenital long QT syndrome or corrected QT interval by Fridericia (QTcF) interval \\>450 msec (males) or \\>470 msec (females).\n6. History of cerebrovascular accident within 6 months or that resulted in ongoing neurologic instability.\n7. History of other previous or concurrent cancer that would interfere with the determination of safety.\n8. Major active infection requiring antibiotics.\n9. Known active human immunodeficiency virus infection or active infection with Hepatitis B or C.\n10. Acute illness within 14 days prior to study Day 1unless mild in severity, as assessed by the Investigator.\n11. Any other condition that in the opinion of the Investigator would place the subject at an unacceptable risk or cause the subject to be unlikely to fully participate or comply with study procedures.\n\nHealthy Volunteers\n\nInclusion Criteria:\n\n1. Healthy male or non-pregnant, non-lactating female subjects aged between 18 and 59 years (inclusive).\n2. Female subjects of childbearing potential and male subjects (if sexually active) must agree to use adequate method(s) of effective contraception during their participation in the study.\n3. Body mass index between 18.0 and 32.0 kg/m2 (inclusive).\n4. Adequate renal function as measured by creatinine clearance calculated at ≥60 mL/minute by the Cockcroft-Gault formula.\n5. Able to understand and willing to sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Prior unilateral or bilateral adrenalectomy.\n2. Mental or legal incapacitation.\n3. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).\n4. Subjects diagnosed with adrenal disease, including Cushing's syndrome, adrenal insufficiency, or congenital adrenal hyperplasia.\n5. Glucocorticoid steroid use (including topical) within 4 weeks prior to study Day 1 (inhaled steroids are allowed).\n6. Active or recent (within 30 days of screening) infection or history of recurrent chronic infections with underlying condition that may predispose one to infections.\n7. Resting pulse rate ≥100 or \\<40 beats per minute at screening. If abnormal, a repeat measurement will be conducted to confirm.\n8. Systolic blood pressure \\>160 or \\<90 mmHg or diastolic blood pressure \\>90 or \\<50 mmHg, unless judged by the Investigator to have no clinical significance.\n9. Participation in a clinical study involving administration of an investigational drug in the past 30 days or 5 half-lives (whichever is longer) prior to study Day 1.\n10. Administered a radionuclide within a period of time corresponding to less than 10 physical half-lives of the radionuclide prior to study Day 1.\n11. Donation of blood or significant blood loss within 3 months prior to screening, donation of plasma within 2 weeks prior to screening, or donation of platelets within 6 weeks prior to screening."}, 'identificationModule': {'nctId': 'NCT05999292', 'briefTitle': 'Phase 1 Study of 68Ga-R8760', 'organization': {'class': 'INDUSTRY', 'fullName': 'Radionetics Oncology'}, 'officialTitle': 'Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients With Adrenocortical Carcinoma and Healthy Volunteers', 'orgStudyIdInfo': {'id': 'R8760-101'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'OTHER', 'label': '68Ga-R8760 Dose Selection (Part 1)', 'interventionNames': ['Drug: 68Ga-R8760 injection at pre-defined dose levels']}, {'type': 'OTHER', 'label': '68Ga-R8760 Expansion Cohort (Part 2)', 'interventionNames': ['Drug: 68Ga-R8760 injection']}], 'interventions': [{'name': '68Ga-R8760 injection at pre-defined dose levels', 'type': 'DRUG', 'description': 'PET/CT imaging at predefined timepoints', 'armGroupLabels': ['68Ga-R8760 Dose Selection (Part 1)']}, {'name': '68Ga-R8760 injection', 'type': 'DRUG', 'description': 'PET/CT imaging at a single timepoint', 'armGroupLabels': ['68Ga-R8760 Expansion Cohort (Part 2)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan Nuclear Medicine', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Radionetics Oncology', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}